Vortx Rx系统组织碎化术治疗前列腺增生的首例人体安全性与疗效
前瞻性单臂研究纳入25例中重度下尿路症状、前列腺30-80g且无前列腺癌证据的男性,经会阴组织碎化术治疗。无严重术中不良事件,但未见目标组织减容,尿流率及残余尿无临床意义改善;IPSS在1、3、6个月分别改善12.5、11.9、10.4分(P<.001)。结论认为该治疗安全且耐受性好,并改善下尿路症状。
要点
- 组织碎化术治疗前列腺增生在首例人体试验中安全且耐受性良好。
- 术后未见目标前列腺组织减容,尿流率及残余尿无临床意义改善。
- IPSS在1、3、6个月分别改善12.5、11.9、10.4分(P<.001)。
核心结论
- 前列腺组织碎化术在该首例人体试验中安全且耐受性良好,并改善下尿路症状。
研究设计与样本
- 前瞻性单臂研究,在2个中心纳入25例中重度下尿路症状、前列腺大小30至80g且无前列腺癌证据的男性受试者。
- 治疗采用Vortx Rx系统经会阴传递声能,并整合实时经直肠超声监测。
- 随访在术后第1天及1、3、6个月进行。
主要发现
- 25例男性接受组织碎化术治疗,无严重术中不良事件。
- 术后设备相关不良事件包括3例短暂性尿潴留(<3天)、1例尿潴留(持续8天,定义为严重)、1例轻微肛门擦伤和镜下血尿。
- 经直肠超声成像或内镜可视化未观察到目标前列腺组织减容,尿流率或排尿后残余尿(PVR)未出现临床意义改善。
- IPSS在1个月改善12.5(52.4%)±6.6分(n=25),3个月改善11.9(50.8%)±7.6分(n=24),6个月改善10.4(44.0%)±7.6分(n=24)(P<.001)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess clinical safety (primary) and efficacy (secondary) of histotripsy for treatment of symptomatic benign prostatic enlargement in a first-in human study. METHODS: Twenty-five male subjects with moderate to severe lower urinary tract symptoms, prostate size between 30 and 80 g, and no evidence of prostate cancer were enrolled at 2 sites in a prospective, single-arm study. Treatment consisted of acoustic energy delivery through the perineum with integrated real-time transrectal ultrasound monitoring using the Vortx Rx system. Follow-up evaluations were performed on postoperative day 1 and 1, 3, and 6 months. RESULTS: Twenty-five men underwent histotripsy treatment with no serious intraoperative adverse events. Postoperatively, 3 cases of transient urinary retention (<3 days), 1 case of urinary retention (8 days in duration, defined as serious), a minor anal abrasion, and microscopic hematuria were considered device-related adverse events. Debulking of targeted prostate tissue was not observed with transrectal ultrasound imaging or with endoscopic visualization, and clinically meaningful improvement in uroflow or postvoid residual urine (PVR) did not occur. However, International Prostate Symptom Score improvement at 1 month was 12.5 (52.4%) ± 6.6 points (n = 25), at 3 months was 11.9 (50.8%) ± 7.6 points (n = 24), and at 6 months was 10.4 (44.0%) ± 7.6 points (n = 24) (P <.001). CONCLUSION: Prostate histotripsy was safe and well tolerated in this pilot human trial with improvement in lower urinary tract symptoms.
引用
- Schuster TG, Wei JT, Hendlin K, et al. Histotripsy Treatment of Benign Prostatic Enlargement Using the Vortx Rx System: Initial Human Safety and Efficacy Outcomes. Urology. 2018. PMID: 29330000. doi:10.1016/j.urology.2017.12.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。